Cramer Rosenthal McGlynn’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,624,180	Closed	-$30.3M	–	106
2022 Q1	$30.3M	Sell	1,624,180 -149,301	-8%	-$2.69M	1.18%	33
2021 Q4	$37.9M	Sell	1,773,481 -50,519	-3%	-$995K	1.22%	31
2021 Q3	$33.7M	Buy	1,824,000 +140,800	+8%	+$2.84M	1.15%	31
2021 Q2	$36M	Sell	1,683,200 -107,655	-6%	-$2.19M	1.16%	30
2021 Q1	$34.6M	Buy	+1,790,855	New	+$31.6M	1.15%	34

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cramer Rosenthal McGlynn's OCDX Position: Q2 2022 in Review

Cramer Rosenthal McGlynn sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 1,624,180 shares — an estimated $30.3M sold.

Cramer Rosenthal McGlynn first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $37.9M in Q4 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

Cramer Rosenthal McGlynn reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Cramer Rosenthal McGlynn sold 1,624,180 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $30.3M.
Cramer Rosenthal McGlynn first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
Cramer Rosenthal McGlynn's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $37.9M in Q4 2021.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Cramer Rosenthal McGlynn's 13F filing for Q2 2022, filed 12 Aug 2022.